Could a common diabetes drug help heal fatty liver?
NCT ID NCT06982378
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This study looks at whether a GLP-1 receptor agonist, a drug already used for diabetes and obesity, can improve fat buildup in the liver and blood in people with MASLD. Researchers will measure changes in fats, proteins, and genes in 30 participants who already take the drug. The goal is to understand how the drug affects liver health at a molecular level.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 receptor agonist
What this could lead to
If successful, this could show that GLP-1 receptor agonists improve liver fat and related metabolic issues in people with MASLD, pointing toward a better treatment approach.
What could go wrong
This is a small, early-stage study (30 people) that only looks at changes in lab markers, not long-term health outcomes. It may not prove the drug works for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.